ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Dianthus Therapeutics Inc

Dianthus Therapeutics Inc (DNTH)

23.38
-0.96
(-3.94%)
Closed 12 March 7:00AM
23.38
0.00
(0.00%)
After Hours: 10:55AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
23.38
Bid
23.00
Offer
27.10
Volume
299,958
22.35 Day's Range 24.315
18.13 52 Week Range 33.77
Market Cap
Previous Close
24.34
Open
24.23
Last Trade Time
Financial Volume
US$ 6,960,987
VWAP
23.2065
Average Volume (3m)
238,336
Shares Outstanding
29,596,965
Dividend Yield
-
PE Ratio
-15.89
Earnings Per Share (EPS)
-1.47
Revenue
2.83M
Net Profit
-43.56M

About Dianthus Therapeutics Inc

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiat... Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Dianthus Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DNTH. The last closing price for Dianthus Therapeutics was US$24.34. Over the last year, Dianthus Therapeutics shares have traded in a share price range of US$ 18.13 to US$ 33.77.

Dianthus Therapeutics currently has 29,596,965 shares in issue. The market capitalisation of Dianthus Therapeutics is US$720.39 million. Dianthus Therapeutics has a price to earnings ratio (PE ratio) of -15.89.

DNTH Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
13.5117.664821338719.8724.80518.1322886422.71348193CS
40.331.43167028223.0525.45518.1323341922.59204175CS
12-0.75-3.1081641110724.1328.6518.1323833622.67157317CS
26-4.25-15.381831342727.6331.9718.1324353724.7381096CS
52-1.77-7.0377733598425.1533.7718.1322727325.45951364CS
15612.98124.80769230810.433.776.5817207124.71142122CS
26012.98124.80769230810.433.776.5817207124.71142122CS

DNTH - Frequently Asked Questions (FAQ)

What is the current Dianthus Therapeutics share price?
The current share price of Dianthus Therapeutics is US$ 23.38
How many Dianthus Therapeutics shares are in issue?
Dianthus Therapeutics has 29,596,965 shares in issue
What is the market cap of Dianthus Therapeutics?
The market capitalisation of Dianthus Therapeutics is USD 720.39M
What is the 1 year trading range for Dianthus Therapeutics share price?
Dianthus Therapeutics has traded in the range of US$ 18.13 to US$ 33.77 during the past year
What is the PE ratio of Dianthus Therapeutics?
The price to earnings ratio of Dianthus Therapeutics is -15.89
What is the cash to sales ratio of Dianthus Therapeutics?
The cash to sales ratio of Dianthus Therapeutics is 244.82
What is the reporting currency for Dianthus Therapeutics?
Dianthus Therapeutics reports financial results in USD
What is the latest annual turnover for Dianthus Therapeutics?
The latest annual turnover of Dianthus Therapeutics is USD 2.83M
What is the latest annual profit for Dianthus Therapeutics?
The latest annual profit of Dianthus Therapeutics is USD -43.56M
What is the registered address of Dianthus Therapeutics?
The registered address for Dianthus Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Dianthus Therapeutics website address?
The website address for Dianthus Therapeutics is www.magentatx.com
Which industry sector does Dianthus Therapeutics operate in?
Dianthus Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RAYRaytech Holding Ltd
US$ 1.69
(94.25%)
104.03M
TSVT2seventy bio Inc
US$ 4.945
(76.61%)
31.49M
HSAIHesai Group
US$ 24.10
(50.53%)
26.82M
SPHLSpringview Holdings Ltd
US$ 6.00
(47.06%)
1.63M
SYRSSyros Pharmaceuticals Inc
US$ 0.1334
(45.63%)
695.66M
WCTWellchange Holdings Company Limited
US$ 0.68417
(-72.74%)
37.72M
ARVNArvinas Inc
US$ 8.29
(-52.79%)
19.03M
LZMHLZ Technology Holdings Ltd
US$ 8.011
(-48.84%)
685.95k
HTCOHigh Trend International Group
US$ 1.41
(-33.80%)
188.46k
SPGCSacks Parente Golf Inc
US$ 0.1061
(-33.73%)
36.38M
SYRSSyros Pharmaceuticals Inc
US$ 0.1334
(45.63%)
695.66M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0402
(20.00%)
411.84M
NVDANVIDIA Corporation
US$ 108.76
(1.66%)
354.43M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 7.93
(7.45%)
304.67M
CUTRCutera Inc
US$ 0.1079
(-16.03%)
218.46M

Your Recent History

Delayed Upgrade Clock